Internet Surveys and Their Impact on Adherence for Rosacea
Condition: Rosacea
MeSH terms: Rosacea
Intervention: brimonidine topical gel 0.33% & survey; brimonidine topical gel 0.33% & SOC
Intervention description: The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.; All subjects will receive standard-of-care brimonidine topical gel 0.33%
Intervention MeSH terms: Brimonidine Tartrate
Phase: Phase 4
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Investigator)
Enrollment: 20.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      An investigator-blinded, prospective, 6 month study of subjects with persistent erythema
      associated with active rosacea will be conducted in 20 subjects aged 18 years and older. All
      subjects will receive standard-of-care brimonidine topical gel, 0.33% with instructions to
      apply it once daily per package insert. Adherence will be assessed using weekly internet
      surveys to document how often the medication is being used, as well as reminders about
      rosacea triggers and general use of brimonidine.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subject with persistent erythema associated with rosacea, age greater
             than 18, who agrees to participate and provide written consent.

          -  Have an Investigator Global Assessment of mild to moderate rosacea (IGA rating between
             2 and 5 in the Investigator Global Assessment score which includes erythema in the
             assessment).

          -  Access to a computer and the internet.

        Exclusion Criteria:

          -  Initiation or change in dose within 4 weeks of baseline of systemic anti-inflammatory
             medication which may influence study outcome.

          -  Use of topical therapy for rosacea within 2 weeks of baseline.

          -  Use of systemic corticosteroids within 4 weeks of baseline. Presence of a concurrent
             medical condition or skin condition, which is determined by the investigator to
             potentially interfere with study outcomes or patient assessments.

          -  Subjects with known allergy or sensitivity to bromonidine topical gel, 0.33% or
             components therein.

          -  Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or
             willing to practice effective contraception during the study. Nursing mothers,
             pregnant women and women planning to become pregnant while on study are to be
             excluded.

          -  Subjects with severe cardiovascular disease or vascular insufficiency.